BR112019005318A2 - compostos de aza-indazol para uso em lesões no tendão e/ou ligamento - Google Patents
compostos de aza-indazol para uso em lesões no tendão e/ou ligamentoInfo
- Publication number
- BR112019005318A2 BR112019005318A2 BR112019005318A BR112019005318A BR112019005318A2 BR 112019005318 A2 BR112019005318 A2 BR 112019005318A2 BR 112019005318 A BR112019005318 A BR 112019005318A BR 112019005318 A BR112019005318 A BR 112019005318A BR 112019005318 A2 BR112019005318 A2 BR 112019005318A2
- Authority
- BR
- Brazil
- Prior art keywords
- aza
- tendon
- indazole compounds
- ligament injuries
- compounds
- Prior art date
Links
- 206010061223 Ligament injury Diseases 0.000 title 1
- 208000021945 Tendon injury Diseases 0.000 title 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical class C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 title 1
- 210000002435 tendon Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a um composto de fórmula (i) (i) na forma livre ou na forma de sal farmaceuticamente aceitável, um método para fabricar os compostos da invenção e seus usos terapêuticos. a presente invenção refere-se, ainda, a uma combinação de agentes farmacologicamente ativos e uma composição farmacêutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398865P | 2016-09-23 | 2016-09-23 | |
| PCT/IB2017/055737 WO2018055551A1 (en) | 2016-09-23 | 2017-09-21 | Aza-indazole compounds for use in tendon and/or ligament injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019005318A2 true BR112019005318A2 (pt) | 2019-09-03 |
Family
ID=60164748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019005318A BR112019005318A2 (pt) | 2016-09-23 | 2017-09-21 | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10766894B2 (pt) |
| EP (1) | EP3515913B1 (pt) |
| JP (1) | JP7008065B2 (pt) |
| KR (1) | KR102472017B1 (pt) |
| CN (1) | CN109715629B (pt) |
| AU (1) | AU2017332868B2 (pt) |
| BR (1) | BR112019005318A2 (pt) |
| CA (1) | CA3033253A1 (pt) |
| CL (1) | CL2019000768A1 (pt) |
| CO (1) | CO2019002618A2 (pt) |
| CR (1) | CR20190144A (pt) |
| CU (1) | CU24550B1 (pt) |
| DO (1) | DOP2019000070A (pt) |
| EA (1) | EA039908B1 (pt) |
| EC (1) | ECSP19019613A (pt) |
| ES (1) | ES2924104T3 (pt) |
| IL (1) | IL264763B (pt) |
| JO (1) | JOP20190053A1 (pt) |
| MX (1) | MX2019003373A (pt) |
| MY (1) | MY197464A (pt) |
| PE (1) | PE20191006A1 (pt) |
| PH (1) | PH12019500328A1 (pt) |
| RU (1) | RU2758256C2 (pt) |
| SG (1) | SG11201901249YA (pt) |
| WO (1) | WO2018055551A1 (pt) |
| ZA (1) | ZA201900861B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| JOP20190144A1 (ar) | 2016-12-16 | 2019-06-16 | Janssen Pharmaceutica Nv | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز |
| TW202016110A (zh) | 2018-06-15 | 2020-05-01 | 比利時商健生藥品公司 | Ｊａｋ激酶家族之小分子抑制劑 |
| GB201813312D0 (en) | 2018-08-15 | 2018-09-26 | Modern Biosciences Ltd | Compounds and their therapeutic use |
| WO2020144604A1 (en) | 2019-01-11 | 2020-07-16 | Novartis Ag | Lta4h inhibitors for the treatment of hidradenitis suppurativa |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7105532B2 (en) | 2000-12-19 | 2006-09-12 | Smithkline Beecham Corporation | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| US9554319B2 (en) * | 2005-09-27 | 2017-01-24 | Qualcomm Incorporated | Channel handoff methods in wireless broadcast systems |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| BRPI0811065A2 (pt) | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| US9556201B2 (en) * | 2009-10-29 | 2017-01-31 | Glaxosmithkline Llc | Bicyclic pyridines and analogs as sirtuin modulators |
| JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 脂肪酸シンターゼ阻害剤 |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
| CN105991238A (zh) | 2015-03-06 | 2016-10-05 | 中兴通讯股份有限公司 | 信道状态信息的测量和反馈方法及发送端和接收端 |
| WO2016161571A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
| UY37412A (es) * | 2016-09-23 | 2018-04-30 | Novartis Ag | Compuestos de indazol para uso en lesiones de tendones y/o ligamentos |
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
-
2017
- 2017-06-16 JO JOP/2019/0053A patent/JOP20190053A1/ar unknown
- 2017-09-21 JP JP2019515597A patent/JP7008065B2/ja active Active
- 2017-09-21 MY MYPI2019000712A patent/MY197464A/en unknown
- 2017-09-21 EA EA201990765A patent/EA039908B1/ru unknown
- 2017-09-21 CA CA3033253A patent/CA3033253A1/en active Pending
- 2017-09-21 PE PE2019000681A patent/PE20191006A1/es unknown
- 2017-09-21 CU CU2019000029A patent/CU24550B1/es unknown
- 2017-09-21 EP EP17788297.4A patent/EP3515913B1/en active Active
- 2017-09-21 US US16/335,496 patent/US10766894B2/en active Active
- 2017-09-21 MX MX2019003373A patent/MX2019003373A/es unknown
- 2017-09-21 WO PCT/IB2017/055737 patent/WO2018055551A1/en unknown
- 2017-09-21 BR BR112019005318A patent/BR112019005318A2/pt active Search and Examination
- 2017-09-21 KR KR1020197010513A patent/KR102472017B1/ko active IP Right Grant
- 2017-09-21 ES ES17788297T patent/ES2924104T3/es active Active
- 2017-09-21 CN CN201780057672.8A patent/CN109715629B/zh active Active
- 2017-09-21 CR CR20190144A patent/CR20190144A/es unknown
- 2017-09-21 SG SG11201901249YA patent/SG11201901249YA/en unknown
- 2017-09-21 RU RU2019111886A patent/RU2758256C2/ru active
- 2017-09-21 AU AU2017332868A patent/AU2017332868B2/en not_active Ceased
-
2019
- 2019-02-10 IL IL264763A patent/IL264763B/en active IP Right Grant
- 2019-02-11 ZA ZA2019/00861A patent/ZA201900861B/en unknown
- 2019-02-15 PH PH12019500328A patent/PH12019500328A1/en unknown
- 2019-03-20 DO DO2019000070A patent/DOP2019000070A/es unknown
- 2019-03-20 EC ECSENADI201919613A patent/ECSP19019613A/es unknown
- 2019-03-21 CO CONC2019/0002618A patent/CO2019002618A2/es unknown
- 2019-03-22 CL CL2019000768A patent/CL2019000768A1/es unknown
-
2020
- 2020-07-28 US US16/941,395 patent/US11203595B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| BR112019005318A2 (pt) | compostos de aza-indazol para uso em lesões no tendão e/ou ligamento | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| CL2018002009A1 (es) | Compuestos derivados de ciclopentanoperhidofenantreno, moduladores de fxr; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento de enfermedades colestásicas, fibróticas, hipercolesterolemia, entre otras. | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112016030733A2 (pt) | Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis | |
| BR112015029353A2 (pt) | derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| BR112018001035A2 (pt) | compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos | |
| BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| BR112019007863A2 (pt) | derivados de naftiridinona inovadores e seu uso no tratamento de arritmia | |
| BR112019005578A2 (pt) | compostos de indazol para uso em lesões no tendão e/ou ligamento | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| BR112016023991A2 (pt) | ativadores de herg policíclicos | |
| BR112015019307A2 (pt) | derivados de ácido butanoico substituído com bisfenila como inibidores de nep com eficácia in vivo melhorada | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112017021843A2 (pt) | compostos, uso de um composto, composição farmacêutica, e, método para tratamento e/ou prevenção de uma doença ou condição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |